Vivalis CMO Services: Clone-to-Clinic Capabilities

摘要

Since 2006, Vivalis has operated and maintained a GMP manufacturing facility for the production of monoclonal antibodies, recombinant proteins, and viral-based products. Founded in 1999, Vivalis has developed a series of innovative technologies to address the needs of biopharmaceutical development. These include novel cell substrates, such as our avian EB66~R cell line, which has seen wide application in areas from vaccine manufacturing to monoclonal antibody development. Our CMO services not only include those for clients using the EB66~R cell line, but also other mammalian cell platforms, such as CHO and HEK-293. As a CMO, we remain platform neutral.